Ideas to Innovation

Drugs to Watch: Innovation in Alzheimer’s disease research

About episode

On June 7th, the U.S. Food and Drug Administration approved aducanumab, the first new Alzheimer’s treatment since 2003. Aducanumab is a monoclonal antibody that has been shown to reduce the buildup of a protein known as beta amyloid that some think might be a possible cause of Alzheimer’s disease. While the approval has been applauded by some, it is not without controversy. In this session, we ask our guests how innovation in the search for treatments of Alzheimer’s disease is evolving.


Mei Mei Hu
Chief Executive Officer
Hans J. Moebius
Chief Medical Officer
Athira Pharma
Raymond J Tesi
Chief Executive Officer and Chief Medical Officer
Inmune Bio
Jerre Stead
Executive Chairman and Chief Executive Officer
Clarivate Plc
Jonathan Searles
Senior Director on the CNS/Ophthalmology therapy team

About Ideas to Innovation

“Ideas to Innovation” is a podcast from Clarivate, a global leader in providing solutions to accelerate the lifecycle of innovation, helping customers solve some of the world’s most complex problems. Join Clarivate in conversations with experts and industry leaders to discuss innovation at its core, from science and research to intellectual property and beyond.